APA (7th ed.) Citation

JP, S., A, F., LJ, C., IW, F., L, I., K, K., . . . AD, Z. (2019). Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: The phase II GATHER study. Leukemia & lymphoma, 60(4), 894. https://doi.org/10.1080/10428194.2018.1515940

Chicago Style (17th ed.) Citation

JP, Sharman, et al. "Obinutuzumab Plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-cell Lymphoma: The Phase II GATHER Study." Leukemia & Lymphoma 60, no. 4 (2019): 894. https://doi.org/10.1080/10428194.2018.1515940.

MLA (9th ed.) Citation

JP, Sharman, et al. "Obinutuzumab Plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-cell Lymphoma: The Phase II GATHER Study." Leukemia & Lymphoma, vol. 60, no. 4, 2019, p. 894, https://doi.org/10.1080/10428194.2018.1515940.